MiR-424 and MiR-155 Deregulated Expression in Cytogenetically Normal Acute Myeloid Leukaemia: Correlation with NPM1 and FLT3 Mutation Status

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2012 Jun 12

PMID 22681934

Citations 35

Authors

Isabella Faraoni

Serena Laterza

Davide Ardiri

Claudia Ciardi

Francesco Fazi

Francesco Lo-Coco

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA have a central role in normal haematopoiesis and are deregulated in acute myeloid leukaemia (AML). The purpose of the study was to investigate by qRT-PCR the expression of miRNAs involved in myeloid differentiation (miR-424, miR-155, miR-223, miR-17-5p) in 48 patients with cytogenetically normal AML well characterized for NPM1 and/or FLT3 mutations. Three types of normalization were used for the data validation.

Findings: We found that miR-424 was down-modulated in AMLs with NPM1mutA regardless of FLT3 status. On the contrary, miR-155 showed up-regulation in patients with FLT3 internal tandem duplications (ITD) with or without NPM1 mutations. No significant associations were found by analyzing miR-223 and miR-17-5p in relation to FLT3 and NPM1 status.

Conclusions: This study supports the view that major genetic subsets of CN-AML are associated with distinct miRNA signatures and suggests that miR-424 and miR-155 deregulation is involved in the pathogenesis of CN-AML with NPM1 and FLT3-ITD mutations, respectively.

Citing Articles

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.

Role of microRNAs in Chronic Lymphocytic Leukemia.

Autore F, Ramassone A, Stirparo L, Pagotto S, Fresa A, Innocenti I Int J Mol Sci. 2023; 24(15).

PMID: 37569845 PMC: 10419063. DOI: 10.3390/ijms241512471.

Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia.

Cao Y, Liu Y, Shang L, Chen H, Yue Y, Dong W Int J Clin Oncol. 2022; 27(7):1222-1232.

PMID: 35536524 PMC: 9209371. DOI: 10.1007/s10147-022-02161-5.

Role of Biomarkers in FLT3 AML.

Nitika , Wei J, Hui A Cancers (Basel). 2022; 14(5).

PMID: 35267471 PMC: 8909069. DOI: 10.3390/cancers14051164.

Strategies targeting FLT3 beyond the kinase inhibitors.

Almatani M, Ali A, Onyemaechi S, Zhao Y, Gutierrez L, Vaikari V Pharmacol Ther. 2021; 225:107844.

PMID: 33811956 PMC: 11490306. DOI: 10.1016/j.pharmthera.2021.107844.

References

Marcucci G, Mrozek K, Radmacher M, Garzon R, Bloomfield C . The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2010; 117(4):1121-9. PMC: 3056468. DOI: 10.1182/blood-2010-09-191312. View

Takahashi S . Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011; 4:36. PMC: 3180439. DOI: 10.1186/1756-8722-4-36. View

Russ A, Sander S, Luck S, Lang K, Bauer M, Rucker F . Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011; 96(12):1783-91. PMC: 3232260. DOI: 10.3324/haematol.2011.046888. View

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L . Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010; 85(5):331-9. DOI: 10.1002/ajh.21667. View

Fazi F, Racanicchi S, Zardo G, Starnes L, Mancini M, Travaglini L . Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell. 2007; 12(5):457-66. DOI: 10.1016/j.ccr.2007.09.020. View

Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F . MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol. 2007; 9(7):775-87. DOI: 10.1038/ncb1613. View

Noguera N, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F . Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia. 2005; 19(8):1479-82. DOI: 10.1038/sj.leu.2403846. View

Aqeilan R, Calin G, Croce C . miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2009; 17(2):215-20. DOI: 10.1038/cdd.2009.69. View

Takahashi S . Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011; 4:13. PMC: 3076284. DOI: 10.1186/1756-8722-4-13. View

10.

Havelange V, Garzon R, Croce C . MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer. 2009; 101(5):743-8. PMC: 2736837. DOI: 10.1038/sj.bjc.6605232. View

11.

Garzon R, Garofalo M, Martelli M, Briesewitz R, Wang L, Fernandez-Cymering C . Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008; 105(10):3945-50. PMC: 2268779. DOI: 10.1073/pnas.0800135105. View

12.

OConnell R, Rao D, Chaudhuri A, Boldin M, Taganov K, Nicoll J . Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008; 205(3):585-94. PMC: 2275382. DOI: 10.1084/jem.20072108. View

13.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

14.

Havelange V, Garzon R . MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol. 2010; 85(12):935-42. DOI: 10.1002/ajh.21863. View

15.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

16.

Gee H, Buffa F, Camps C, Ramachandran A, Leek R, Taylor M . The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer. 2011; 104(7):1168-77. PMC: 3068486. DOI: 10.1038/sj.bjc.6606076. View

17.

Pelosi E, Labbaye C, Testa U . MicroRNAs in normal and malignant myelopoiesis. Leuk Res. 2009; 33(12):1584-93. DOI: 10.1016/j.leukres.2009.04.039. View

18.

Lossner C, Meier J, Warnken U, Rogers M, Lichter P, Pscherer A . Quantitative proteomics identify novel miR-155 target proteins. PLoS One. 2011; 6(7):e22146. PMC: 3143118. DOI: 10.1371/journal.pone.0022146. View

19.

Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis F, Marchioni M . The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci U S A. 2007; 104(50):19849-54. PMC: 2148386. DOI: 10.1073/pnas.0706963104. View

20.

Starnes L, Sorrentino A, Pelosi E, Ballarino M, Morsilli O, Biffoni M . NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood. 2009; 114(9):1753-63. DOI: 10.1182/blood-2008-12-196196. View